Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axitinib and Sandostatin LAR in Advanced Non-pancreatic Neuroendocrine Tumors
NCT01744249Phase 3Completed
- Sponsor
- Spanish Group of Neuroendocrine Tumors
- Start
- Nov 2011
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 3 trial of axitinib in neuroendocrine tumors (NETs), sponsored by Spanish Group of Neuroendocrine Tumors. Started Nov 2011; status: completed.
02
Drugs
axitinib
03
Conditions
neuroendocrine tumors (NETs)
Beyond the preview
Go deeper on NCT01744249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01744249.